Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

TCT 2021 | SIERRA trial updates: apamistamab in AML

Tania Jain, MBBS, Johns Hopkins University, Baltimore, MD, outlines key updates in the treatment of leukemia as presented at this year’s Transplantation & Cellular Therapy (TCT) 2021 meeting including two abstracts evaluating the use of targeted radioimmunotherapy with an anti-CD45 antibody, apamistamab (Iomab-B) in patients with acute myeloid leukemia. This interview took place during the Transplantation & Cellular Therapy (TCT) 2021 Meetings.